摘要
Pancreatic ductal adenocarcinoma accounts for the primary type of pancreatic cancer(PC)with a 5-year survival rate of only about 10%in the United States.Early diagnosis will improve chances for curative treatment.To date,a broadly used serum marker for PC diagnosis is carbohydrate antigen 19-9,which is the only approved biomarker currently by the United States Food and Drug Administration.However,it has low specificity;therefore,development of novel biomarkers is urgently needed.Clinical trials are ongoing to evaluate candidate biomarkers for PC diagnosis,and the use of a multi-biomarker panel with current PC diagnostic biomarkers appears promising.
